HCW Biologics (HCWB) to Release Earnings on Wednesday

Posted by Jessica Moore on Mar 30th, 2026

HCW Biologics (NASDAQ:HCWB – Get Free Report) is projected to release its results before the market opens on Wednesday, April 1st. Analysts expect HCW Biologics to post earnings of ($0.84) per share and revenue of $7.0120 million for the quarter.

HCW Biologics Stock Performance

HCWB opened at $0.40 on Monday. The company has a market cap of $1.40 million, a price-to-earnings ratio of -0.03 and a beta of 0.79. HCW Biologics has a one year low of $0.36 and a one year high of $17.80. The business’s fifty day moving average is $0.81 and its two-hundred day moving average is $2.10.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC purchased a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned approximately 9.15% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 2.96% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, HCW Biologics currently has a consensus rating of “Hold” and an average target price of $35.00.

Get Our Latest Stock Analysis on HCWB

About HCW Biologics

(Get Free Report)

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.